Keeping Track: US FDA Approves Korsuva, Skytrofa And Comirnaty, But Tecentriq Loses TNBC Indication

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

The US FDA’s Center for Drug Evaluation and Research produced two novels approvals, for Cara Therapeutics, Inc.’s Korsuva and Ascendis Pharma A/S’s Skytrofa, after the Center for Biologics Evaluation and Research opened last week with the highly publicized full approval of Pfizer Inc./BioNTech SE’s COVID-19 vaccine Comirnaty.

In oncology, however, the biggest news was a withdrawal, not an approval, as Genentech, Inc.’s Tecentriq lopped a “dangling”...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers